Aim To assess adverse outcomes attributable to non‐cardiac co‐morbidities and to compare
their effects by left ventricular ejection fraction (LVEF) group [LVEF< 50%(heart failure with …

Background Heart failure (HF) and non-cardiac comorbidities often coexist and are known to
have an adverse effect on outcome. However, the prevalence and prognostic impact of non …

Aims The prevalence of cardiovascular and non‐cardiovascular co‐morbidities and their
relative importance for outcomes in heart failure with preserved ejection fraction (HFPEF) …

Objectives: The aim of this study was to evaluate the prevalence and prognostic impacts of
noncardiac comorbidities in patients with heart failure (HF) with preserved ejection fraction …

Background Comorbidities play a major role in heart failure. Whether prevalence and
prognostic importance of comorbidities differ between heart failure with preserved ejection …

Aims The aim of this analysis was to provide data on the overall comorbidity burden, both
cardiovascular (CV) and non‐CV, in a large real‐world heart failure (HF) population across …

Aims The prognostic impact of coronary artery disease (CAD) in heart failure is debated.
Whereas causes of death have been well described in patients with cardiomyopathy, little is …

Aim Patients with heart failure (HF) often suffer from a range of comorbidities, which may
affect their health status. The aim of this study was to assess the impact of different …

Several co‐existing diseases and/or conditions (co‐morbidities) are present in patients with
heart failure (HF), with diverse clinical relevance. Multiple mechanisms may underlie the co …

Aims Whether prevalence and mortality of patients with heart failure with preserved or mid-
range (40–49%) ejection fraction (HFpEF and HFmREF) are similar to those of heart failure …